Ali Dianaty - 09 Mar 2026 Form 4 Insider Report for MiniMed Group, Inc. (MMED)

Reporting relationship: EVP, Chief Product & Technology Officer
Issuer ticker: MMED
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 16:30:37 UTC
Prior SEC filing: 06 Mar 2026
Next SEC filing: 13 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Bryan F. Kelly, attorney-in-fact

Key filing fact

Ali Dianaty filed Form 4 for MiniMed Group, Inc. (MMED) on 11 Mar 2026.

Key facts

This page summarizes Ali Dianaty's Form 4 filing for MiniMed Group, Inc. (MMED).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002111492 Primary reporting owner

Dianaty Ali

Relationship: EVP, Chief Product & Technology Officer
Address: C/O 18000 DEVONSHIRE STREET, NORTHRIDGE
Signature: /s/ Bryan F. Kelly, attorney-in-fact
Signature date: 11 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MMED transaction Derivative

Performance-Based Restricted Stock Units

Award

Transaction value
Shares: +13,889
Change %
Price: $0.000000^*
Shares after: 13,889
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,889
Exercise price
Footnotes: F1, F2

MMED transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +126,263
Change %
Price: $0.000000^*
Shares after: 126,263
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 126,263
Exercise price: $18.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

Footnote F2

The later of March 9, 2027 or the Divestment Date.

Footnote F3

The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC remarks

EVP, Chief Product & Technology Officer